H.C. Wainwright lowered the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports Q3 2025 Financial Results
- MoonLake Immunotherapeutics price target raised to $30 from $25 at Oppenheimer
- MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
- MoonLake Immunotherapeutics Announces $75M Share Offering
- MoonLake Immunotherapeutics’ SLK Program: Buy Rating Backed by Promising Trial Results and Upcoming Catalysts